RecruitingNCT01257269

Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)

Thrombotic Thrombocytopenic Purpura Registry - A Prospective Observational Study for Patients Suffering From Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)


Sponsor

Insel Gruppe AG, University Hospital Bern

Enrollment

450 participants

Start Date

Oct 1, 2006

Study Type

OBSERVATIONAL

Conditions

Summary

Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) deficiency which is the result of compound heterozygous or homozygous ADAMTS13 gene mutations. Although considered a monogenic disorder the clinical presentation in Upshaw-Schulman syndrome patients varies considerably without an apparent genotype-phenotype correlation. In 2006 we have initiated a registry for patients with Upshaw-Schulman syndrome and their family members to identify possible triggers of acute bouts of TTP, to document individual clinical courses and treatment requirements as well as possible side effects of long standing plasma substitution, e.g. alloantibody formation or viral infections.


Eligibility

Plain Language Summary

Simplified for easier understanding

This study examines hereditary thrombotic thrombocytopenic purpura (TTP), also called Upshaw-Schulman syndrome — a rare blood disorder in which blood clots form in small vessels throughout the body. It is caused by a severe inherited deficiency of an enzyme called ADAMTS13. Researchers collect genetic, clinical, and laboratory data to understand how different mutations cause different disease patterns and outcomes. You may be eligible if... - You have a confirmed severe deficiency of the ADAMTS13 enzyme (10% or less activity) on two separate occasions, without an inhibitor to ADAMTS13 - You have one or more mutations in the ADAMTS13 gene - You responded to fresh frozen plasma infusion (a positive infusion trial) - You are a family member of a confirmed or suspected patient You may NOT be eligible if... - You do not meet the laboratory or genetic criteria listed above - You are a family member who declines to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERObservation

No interventions planned: treatment of patients at the discretion of the treating/responsible physician


Locations(7)

University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901

Oklahoma City, Oklahoma, United States

Medical University of Vienna, Department of Medicine 1, Div. Hematology and Hemostasis Waehringer Guertel 18-20

Vienna, Austria

Institute of Hematology and Blood Transfusion, Coagulation Laboratory, U nemocnice 1

Prague, Czechia

University Medical Center Hamburg-Eppendorf, Department of Pediatric Hematology and Oncology, Martinistr 52

Hamburg, Germany

Nara Medical University, Department of Blood Transfusion Medicine, Shijyo-cho 840

Kashihara, Nara, Japan

Trondheim University St Olavs Hospital, Department of Hematology, PO Box 3250 Sluppen

Trondheim, Norway

University Clinic of Hematology and Central Hematology Laboratory, Bern University Hospital and the University of Bern, Inselspital

Bern, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT01257269


Related Trials